Welcome to Hmobio!Global leader in active molecules.
Find Your Distributors

Select Your Country or Region

 $ USD

For research purposes only. Not for human experiments
You are here:Home-Research Areas-Cardiovascular Disease-Coagulation Disorder

Request The Product List ofCoagulation Disorder Coagulation Disorder

Octapharma develops and manufactures high-purity coagulation factor concentrates for patients with bleeding disorders.

These plasma products are produced to the highest standards, using the latest technology, in state-of-the-art manufacturing facilities to ensure the most advanced solutions are available to patients globally.  

Bleeding disorders

"Bleeding disorder" is a general term for a wide range of medical problems that lead to poor blood clotting and continuous bleeding, including:

~Hemophilia A

~von Willebrand disease (VWD)

In people with such disorders, clotting factors like Factor VIII, Factor IX or von Willebrand factor (VWF) are missing or don't work as they should. This causes these people to bleed for a longer time than those whose blood factor levels are normal. Early on-demand or prophylactic therapy that replaces the missing coagulation factor is able to effectively control or prevent acute bleeding in this group of patients.

Cat. No. Product Name CAS No. Information
H6727

TCV-309 chloride

 		121494-09-5

A highly potent and selective platelet activating factor (PAF) antagonist; inhibits PAF-induced aggregation of rabbit and human platelets with IC50s of 33 nM and 55 nM respectively; potently protects mice from death induced by PAF and due to anaphylactic shock with ED50 of 2.1 and 2.6 ug/kg (i.v.), respectively; also reverses PAF-induced hypotension and endotoxin-induced hypotension in rats.
H3798

TCV-309

 		131311-25-6

A highly potent and selective platelet activating factor (PAF) antagonist; inhibits PAF-induced aggregation of rabbit and human platelets with IC50s of 33 nM and 55 nM respectively; potently protects mice from death induced by PAF and due to anaphylactic shock with ED50 of 2.1 and 2.6 ug/kg (i.v.), respectively; also reverses PAF-induced hypotension and endotoxin-induced hypotension in rats.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 HmoBio. All Rights Reserved. Products are only for research use
沪ICP备2020027822号-1